Stryker (NYSE:SYK) reported Q1 2026 EPS of USD 2.60, missing consensus of USD 2.98, as a cyber incident disrupted operations for nearly three weeks. Despite the shortfall, the company maintained full-year guidance of USD 14.90 to USD 15.10 adjusted EPS, citing strong underlying Demand and record Mako installations.

Key Highlights

  • Stryker reported Q1 2026 adjusted EPS of USD 2.60, missing consensus of USD 2.98 by 12.75%, down 8.5% year over year.
  • Revenue of USD 6.02 billion fell short of the anticipated USD 6.35 billion, with Organic Sales growth of just 2.4% due to cyber-related operational disruption.
  • The company maintained full-year 2026 guidance of adjusted EPS between USD 14.90 and USD 15.10 and Organic Sales growth of 8% to 9.5%.
  • Mako robotic-assisted surgery achieved its best ever Q1 installation record in both the United States and internationally.
  • A cyber incident, attributed to an Iranian-linked hacking group, disrupted global operations for approximately three weeks late in the quarter.

Earnings Performance and the Cyber Incident's Distorting Effect

Stryker's (NYSE:SYK) Q1 2026 results were structurally compromised by a cyber incident that struck late in the quarter, wiping approximately 40,000 laptops and forcing a global shutdown of Manufacturing and logistics systems for close to three weeks. The timing was particularly consequential. Because the disruption occurred toward the end of the quarter, the impact on Revenue recognition was disproportionately large relative to the duration of the outage. Adjusted EPS of USD 2.60 fell significantly below the consensus estimate of USD 2.98, and total Revenue of USD 6.02 billion missed the anticipated USD 6.35 billion.

Management was explicit that these results are not indicative of underlying market performance or Business momentum. The company was fully operational across its global Manufacturing network by the week of April 1, and the order book remained elevated entering the remainder of the year. The decision to maintain full-year guidance, rather than revise it downward, is the most analytically significant signal from this report. It implies that management is confident the deferred Revenue, delayed shipments, and rescheduled procedures are recoverable, with most expected to normalise across Q2 through Q4.

Segment Dynamics and the Uneven Impact of the Incident

The cyber disruption affected Stryker's two principal segments in materially different ways. The orthopedics segment, which includes joint replacement and trauma businesses, generated sales of USD 2.81 billion, up 6.3% year over year, beating analyst estimates of USD 2.51 billion. This relative resilience reflects the nature of the orthopedic Business model, where consigned inventory is typically held at hospital sites rather than centrally within the Supply chain, allowing many procedures to proceed even during the system outage. However, Revenue recognition delays will push a portion of Q1 billings into Q2.

The medical surgery and neurotechnology segment, which covers Capital-intensive products such as beds, stretchers, defibrillators, and endoscopy equipment, was more severely impacted. Sales of USD 3.21 billion rose only 5%, significantly below analyst estimates of USD 3.83 billion. This segment includes make-to-order products with longer fulfillment cycles that require full system functionality to manufacture and ship. Production shutdowns during the incident created backlogs that management expects to clear primarily in Q3 and Q4 rather than Q2.

Adjusted gross Margin contracted 190 basis points year over year to 63.6%, driven by lost Manufacturing absorption during the shutdown and incremental Tariff costs. Adjusted operating Margin declined 180 basis points to 21.1%, reflecting gross Margin pressure compounded by Operating Expense deleveraging on lower Revenue.

Mako Platform and Innovation Pipeline Remain Structurally Compelling

Despite the headline disruption, the qualitative picture for Stryker's innovation cycle remains constructive. The Mako robotic-assisted surgery platform achieved a record Q1 for new installations in both the United States and internationally, with management noting the figure would have been higher absent the cyber-induced shipping constraints. Mako 4, the latest generation of the platform, is receiving strong surgeon feedback, particularly for its expanded multifunctionality across revision hip, knee, and the forthcoming Mako Shoulder indication, expected to fully launch mid-year.

The company also introduced Mako RPS, a handheld robotic solution positioned below the full Mako system in terms of Capital commitment, which is gaining traction in ambulatory surgical centres among surgeons not yet ready to adopt a full robotic platform. Management described early trialing results as highly positive, with the product targeting an incremental customer segment rather than cannibalising Mako Demand.

The Pangea trauma plating system, which has driven above-market growth in the United States, received European regulatory approval during the quarter. LIFEPAK 35, a next-generation defibrillator, is now approved across most major global markets. Both products are expected to serve as growth tailwinds into 2027 and 2028 given their multi-year replacement cycles.

M&Amp;A Activity and Capital Deployment

Stryker announced an agreement to acquire Amplitude Vascular Systems, a peripheral vascular company developing intravascular lithotripsy technology, expected to close in Q2. The Acquisition expands Stryker's footprint in peripheral and interventional cardiovascular procedures, complementing the Inari Medical platform acquired in 2025. Management indicated the company ended the quarter at 2.1 times gross Debt to EBITDA, providing meaningful capacity for continued M&Amp;A activity through the remainder of 2026 and into 2027.

The Smart Hospital initiative, combining Vocera communication software and Care AI monitoring with ProCuity smart beds, officially launched in March and is building early commercial momentum, with management describing the integration as receiving positive hospital feedback.

Risks Worth Monitoring

The primary near-term risk is execution against the recovery timeline. The full-year guidance reiteration is contingent on recapturing deferred Revenue across three quarters, a task made more complex by the varied operating models across segments. Tariff headwinds represent a persistent Margin pressure that management has factored into guidance but acknowledged may intensify. The cyber incident itself raises structural questions around Cybersecurity Investment requirements, and management confirmed additional investments are contemplated within the existing guidance envelope. Competitive dynamics in orthopedics, with peers reorganising sales forces and ownership structures, may create near-term uncertainty, though Stryker's robotic Leadership position and order book strength provide a degree of insulation.